

Antibody-drug conjugate
 Antibody or antibody fragment
 Antisense oligonucleotide
 Protein
 Pegylated hormone
 Small interfering RNA
 Small molecule

Steady clip

In 2021, the US Food and Drug Administration approved 50 new drugs, a similar number to that of past years despite the ongoing pandemic.

DRUG NAME	ACTIVE INGREDIENT	MARKETER	INDICATION	MECHANISM OF ACTION
Adbry	Tralokinumab	Leo Pharma	Moderate to severe atopic dermatitis	Interleukin-13 antagonist
Leqvio	Inclisiran	Novartis	Heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease	Directs the catalytic breakdown of messenger RNA for PCSK9
Vyvgart	Efgartigimod alfa	Argenx	Generalized myasthenia gravis	Neonatal Fc receptor binder
Tezspire	Tezepelumab	AstraZeneca	Add-on maintenance therapy for severe asthma	Blocks thymic stromal lymphopoietin
Cytalux	Pafolacianine	On Target Laboratories	Identification of ovarian cancer lesions	Binds to cancer cells that express the folate receptor
Livtency	Maribavir	Takeda Pharmaceuticals USA	Posttransplant cytomegalovirus infection or disease that does not respond to available antiviral treatment	Antiviral
Voxzogo	Vosoritide	BioMarin Pharmaceutical	Achondroplasia and open epiphyses in children 5 and older	Positive regulator of endochondral bone growth
Besremi	Ropeginterferon alfa-2b	PharmaEssentia	Polycythemia vera	Interferon alfa receptor binder
Scemblix	Asciminib	Novartis	Philadelphia chromosome–positive chronic myeloid leukemia	Kinase inhibitor
Tavneos	Avacopan	ChemoCentryx	Severe active antineutrophil cytoplasmic autoantibody–associated vasculitis	C5a receptor antagonist
Livmarli	Maralixibat	Mirum Pharmaceuticals	Cholestatic pruritus in people with Alagille syndrome	Ileal bile acid transporter inhibitor
Qulipta	Atogepant	AbbVie	Episodic migraines	Calcitonin gene–related peptide receptor antagonist
Tivdak	Tisotumab vedotin	Genmab and Seagen	Recurrent or metastatic cervical cancer	Tissue factor–directed antibody and microtubule inhibitor
Exkivity	Mobocertinib	Takeda Pharmaceutical	Locally advanced or metastatic non-small-cell lung cancer with exon 20 insertion mutations in the epidermal growth factor receptor	Kinase inhibitor
Skytrofa	Lonapegsomatropin	Ascendis Pharma	Short stature due to inadequate secretion of endogenous growth hormone	Long-acting prodrug of human growth hormone
Korsuva	Difelikefalin	Vifor Pharma	Moderate to severe pruritus associated with chronic kidney disease	Kappa opioid receptor agonist
Welireg	Belzutifan	Merck & Co.	Von Hippel–Lindau disease	Hypoxia–inducible factor–2 α inhibitor
Nexvazyme	Avalglucosidase alfa	Genzyme	Late-onset Pompe disease	Enzyme replacement therapy
Saphnelo	Anifrolumab	AstraZeneca	Systemic lupus erythematosus	Type I interferon receptor antagonist
Bylvay	Odevixibat	Albireo Pharma	Pruritus	Ileal bile acid transporter inhibitor
Rezurock	Belumosudil	Kadmon	Chronic graft–versus–host disease	Kinase inhibitor
Fexinidazole	Fexinidazole	Sanofi–Aventis US	Human African trypanosomiasis	Trypanocidal
Kerendia	Finerenone	Bayer HealthCare Pharmaceuticals	Kidney and heart complications in chronic kidney disease associated with type 2 diabetes	Mineralocorticoid receptor antagonist
Rylaze	Asparaginase erwinia chrysanthemi (recombinant)	Jazz Pharmaceuticals	Acute lymphoblastic leukemia and lymphoblastic lymphoma in people who are allergic to <i>Escherichia coli</i> –derived asparaginase products	Catalyzes the conversion of asparagine into aspartic acid and ammonia
Aduhelm	Aducanumab	Biogen	Alzheimer’s disease	Anti-amyloid- β antibody
Brexafemme	Ibrexafungerp	Scynexis	Vulvovaginal candidiasis	Triterpenoid antifungal
Lybalvi	Olanzapine and samidorphan	Alkermes	Schizophrenia or bipolar I disorder	Unknown
Truseltiq	Infigratinib	QED Therapeutics	Cholangiocarcinoma	Kinase inhibitor
Lumakras	Sotorasib	Amgen	Non-small-cell lung cancer	KRAS G12C inhibitor
Pylarify	Piflufolastat F-18	Progenics Pharmaceuticals	Identification of lesions positive for prostate-specific membrane antigen in people with prostate cancer	Binds to malignant prostate cancer cells
Rybrevant	Amivantamab	Janssen Biotech	Non-small-cell lung cancer	EGFR and MET binder
Empaveli	Pegcetacoplan	Apellis Pharmaceuticals	Paroxysmal nocturnal hemoglobinuria	C3 binder
Zynlonta	Loncastuximab tesirine	ADC Therapeutics	Relapsed or refractory large B-cell lymphoma	CD19 binder and alkylating agent
Jemperli	Dostarlimab	GlaxoSmithKline	Endometrial cancer	PD-L1 and PD-L2 binder
Nextstellis	Drospirenone and estetrol	Mayne Pharma	Prevention of pregnancy	Suppresses ovulation
Qelbree	Viloxazine	Supernus Pharmaceuticals	Attention deficit hyperactivity disorder	Selective norepinephrine reuptake inhibitor
Zegalogue	Dasiglucagon	Zealand Pharma	Severe hypoglycemia	Glucagon receptor agonist
Ponvory	Ponesimod	Janssen Pharmaceuticals	Relapsing forms of multiple sclerosis	Sphingosine 1-phosphate receptor 1 modulator
Fotivda	Tivozanib	Aveo Pharmaceuticals	Renal cell carcinoma	Tyrosine kinase inhibitor
Azstarys	Serdexmethylphenidate and dexamethylphenidate	Corium	Attention deficit hyperactivity disorder	Unknown
Pepaxto	Melphalan flufenamide	Oncopeptides	Relapsed or refractory multiple myeloma	DNA alkylation
Nulibry	Fosdenopterin	Origin Biosciences	Molybdenum cofactor deficiency type A	Provides an exogenous source of cyclic pyranopterin monophosphate
Amondys 45	Casimersen	Sarepta Therapeutics	Duchenne muscular dystrophy	Exclusion of exon 45 during messenger RNA processing
Cosela	Trilaciclib	G1 Therapeutics	Mitigation of chemotherapy–induced myelosuppression in people with small-cell lung cancer	Kinase inhibitor
Evkeeza	Evinacumab	Regeneron Pharmaceuticals	Homozygous familial hypercholesterolemia	ANGPTL3 inhibitor
Ukoniq	Umbalisib	TG Therapeutics	Marginal zone lymphoma or follicular lymphoma	Kinase inhibitor
Tepmetko	Tepotinib	EMD Serono	Non-small-cell lung cancer	Kinase inhibitor
Lupkynis	Voclosporin	Aurinia Pharmaceuticals	Lupus nephritis	Calcineurin inhibitor
Cabenuva	Cabotegravir and rilpivirine	ViiV Healthcare	HIV	HIV-1 antiretrovirals
Verquvo	Vericiguat	Merck & Co.	Chronic heart failure	Soluble guanylate cyclase stimulator

Sources: US Food and Drug Administration, companies. **Note:** Drugs shown in reverse chronological order of approval during 2021.